Global Hunter Syndrome Treatment Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
Request Covid 19 Impact
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
“Global Hunter Syndrome Treatment Market” is the title of a recent report produced by MarketResearch.biz, after thorough analysis and study. The global Hunter Syndrome Treatment market report has been segmented on the basis of treatment, end-user, and region.
Hunters Syndrome, an inherited genetic disorder that is mostly found in men as compared to women. This syndrome is also known as mucopolysaccharidosis type II, occurs because of declining X chromosome in males, and in which large molecules of sugar or glycosaminoglycans or mucopolysaccharides accumulate in tissues of the body. This can further lead to heart-related diseases, respiratory system, and can affect bones and several organs. Individuals suffering from Hunter syndrome suffer from multiple diseases which can lead to death as well.
The major factors driving growth of the market are rapid product pipeline, introduction of new therapies, growing awareness about Hunter syndrome and its various available therapeutic adoptions, and increasing government initiatives. Hunter syndrome, which is also in another name, mucopolysaccharidosis type II (MPS II). There is no complete cure for Hunter syndrome. Different existing treatments such as hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) focus mainly on providing management of complications, which is associated with disease progression, and symptomatic relief. According to the National Institute of Health (NIH), Hunter syndrome affects 1 in 160,000 males. The risk of this disease in women is very less as they have two X chromosomes. Hence, the second one can provide active gene if one of them get affected. However, men do not have the second one to compensate for the defective one. Other factors such as expected approval of new therapies and rising R&D activities are major factors expected to drive growth of the product in the global Hunter syndrome treatment market over the forecast period. In addition, various initiatives taken by organizations to increase awareness about diagnosis of the diseases and treatment are projected to support growth of the market over the forecast period.
Global Hunter Syndrome Treatment Market Segment Analysis:
By Treatment: Among the treatment segments, the Enzyme Replacement Therapy (ERT) accounts for highest revenue share as compared to the other segments. This can be attributed to improved sales.
By End-user: The hospital segment among the end-user segment is expected to dominate the market in terms of revenue share in the global Hunter syndrome treatment market, and the dominance is projected to continue over the forecast period.
Global Hunter Syndrome Treatment Market Regional Analysis:
The North America Hunter syndrome treatment market is expected to account for majority revenue share in the global market, due to presence of favorable government regulations regarding research & development of orphan drugs, prevalence of rare diseases including Hunter syndrome, increasing investments by government and private players for research activities, and for improving healthcare facilities in the region. In addition, favorable and easy reimbursement policies in countries such as the US and Canada for highly expensive drugs including ELAPRASE has resulted in higher adoption of treatment, thus, fueling North America's market growth. The Europe market is projected to account for second-highest revenue share in the market and is projected to register a steady growth rate over the next 10 years. Asia Pacific market is projected to register significantly high CAGR over the 10-year forecast period. In the Asia Pacific, the markets in China, India, and Japan are projected to collectively contribute major revenue share, due to concerns related to unmet needs, which has offered opportunities to players in terms of expansion in the Asia Pacific market. In addition, increasing focus of major players on securing drug approvals in order to sustain in the market is expected to drive market growth in the region. In July 2019 for instance, Beijing-based CANBridge Pharmaceuticals Inc. has filed its New Drug Application with the National Medical Products Administration (NMPA) in China, for – Hunterase – a treatment drug for Hunter syndrome.
Global Hunter Syndrome Treatment Market Segmentation:
- Enzyme Replacement Therapy (ERT)
- Hematopoietic Stem Cell Transplant (HSCT)
- Specialty Care Unit
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Shire Plc. (Takeda Pharmaceutical Company)
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- ArmaGen Inc
- Inventiva S.A.
- Denali Therapeutics Inc.
- Bioasis Technologies Inc.
Request for TOC
Don't just take our word. We are trusted by these great companies!